# Industrialization and Translation of Extracellular Vesicles for use in Regenerative Medicine (U43/U44 Clinical Trials Not Allowed)

Source: https://welltoldgrants.com/grants/par-23-267-industrialization-and-translation-of-extracellular-vesicles/  
Official notice: https://www.grants.gov/search-results-detail/347582

> National Institutes of Health offered grants of up to $295,924 to small businesses. Applications closed on December 9, 2025.

| Field | Value |
|---|---|
| Opportunity number | PAR-23-267 |
| Agency | National Institutes of Health |
| Status | Forecast |
| Deadline | December 9, 2025 |
| Award ceiling | $295,924 |
| Award floor | not stated |
| Expected awards | not stated |
| Total funding | not stated |
| Cost sharing | not required |
| Assistance Listings | 93.350 |

## Who can apply

- Small businesses

Other Eligible Applicants include the following:Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed. See full Notice of Funding Opportunity for additional details on eligibility.

## What the grant funds

This FOA provides support using the SBIR cooperative agreement mechanisms for the development of novel extracellular vesicle-based therapeutic platforms for use in regenerative medicine. Both native and engineered EVs have demonstrated the ability for specific and targeted tissue and organ repair, which can be harnessed for applications such as extracellular vesicle-based therapeutics. The main objective for this funding opportunity is to support platform-oriented technology development associated with the production, manufacturing, and use, of extracellular vesicles as therapeutics in regenerative medicine.

## Questions people ask

### Is PAR-23-267 still open?

No. It closed on December 9, 2025.

### Who can apply for Industrialization and Translation of Extracellular Vesicles for use in Regenerative Medicine (U43/U44 Clinical Trials Not Allowed)?

National Institutes of Health accepted applications from small businesses. The notice adds further conditions, so read its eligibility section.

### What is the deadline for Industrialization and Translation of Extracellular Vesicles for use in Regenerative Medicine (U43/U44 Clinical Trials Not Allowed)?

Closed December 9, 2025. Applications are no longer accepted; the program's newer notices are on this page when there are any.

### How much funding is available?

Awards of up to $295,924 each.

### Who has been funded under PAR-23-267?

NIH RePORTER lists 1 project funded under PAR-23-267 in fiscal 2026, at 1 institution.

### Who has won National Center for Advancing Translational Sciences grants before?

The largest recipients over five fiscal years were University of Pittsburgh - of the Commonwealth System of Higher Education, Vanderbilt University Medical Center, Duke University. The program made 867 awards worth $3.1 billion in that time.